Coupling Kinesin Spindle Protein and Aurora B Inhibition with Apoptosis Induction Enhances Oral Cancer Cell Killing

• Published in: Cancers Vol. 16; no. 11; p. 2014
• Main Authors: Silva, João P N, Pinto, Bárbara, Monteiro, Luís, Silva, Patrícia M A, Bousbaa, Hassan
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 25-05-2024; MDPI
• Subjects: Antimitotic agents; Antineoplastic agents; Apoptosis; Aurora B protein; Aurora kinase; Cancer; Cancer cells; Cancer therapies; Care and treatment; Cell death; Cell division; Clinical trials; Cyclin B; Cytokinesis; Health aspects; Kinases; Kinesin; Laboratories; Medical prognosis; Mitosis; Molecular weight; Mouth cancer; Oral cancer; Physiological aspects; Proteins; Software; Squamous cell carcinoma; Testing; Tongue; Toxicity; Portugal; St Louis Missouri; United States > US; Germany; Aurora B inhibitor; combination treatment; Navitoclax; KSP inhibitor; antimitotics; oral cancer
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers16112014

Many proteins regulating mitosis have emerged as targets for cancer therapy, including the kinesin spindle protein (KSP) and Aurora kinase B (AurB). KSP is crucial for proper spindle pole separation during mitosis, while AurB plays roles in chromosome segregation and cytokinesis. Agents targeting KSP and AurB selectively affect dividing cells and have shown significant activity in vitro. However, these drugs, despite advancing to clinical trials, often yield unsatisfactory outcomes as monotherapy, likely due to variable responses driven by cyclin B degradation and apoptosis signal accumulation networks. Accumulated data suggest that combining emerging antimitotics with various cytostatic drugs can enhance tumor-killing effects compared to monotherapy. Here, we investigated the impact of inhibiting anti-apoptotic signals with the BH3-mimetic Navitoclax in oral cancer cells treated with the selective KSP inhibitor, Ispinesib, or AurB inhibitor, Barasertib, aiming to potentiate cell death. The combination of BH3-mimetics with both KSP and AurB inhibitors synergistically induced substantial cell death, primarily through apoptosis. A mechanistic analysis underlying this synergistic activity, undertaken by live-cell imaging, is presented. Our data underscore the importance of combining BH3-mimetics with antimitotics in clinical trials to maximize their effectiveness.